Your session is about to expire
← Back to Search
Palmitoylethanolamide for Knee Fracture
Phase 2
Waitlist Available
Led By Ariana Nelson, MD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
This trial will study whether the inclusion of PEA (a non-psychoactive cannabis compound) in conjunction with standard post-surgical medications can reduce pain and inflammation while decreasing the number of opioids needed.
Eligible Conditions
- Knee Fracture
- Tibial Fracture
- Fibula Fracture
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
3 month post-surgical NSAID use Questionnaire
3 month post-surgical Opioid use Questionnaire
Secondary outcome measures
Average Pain Interference
Average Pain Scores
Functional Status
+4 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: PalmitoylethanolamideActive Control1 Intervention
300 mg PEA twice a day for a total of 600 mg PEA daily 2-month supply upon discharge
Group II: PlaceboPlacebo Group1 Intervention
1 placebo tablet twice a day for a total of 2 tablet placebo daily 2-month supply upon discharge
Find a Location
Who is running the clinical trial?
GE Nutrients Inc. (Gencor)UNKNOWN
University of California, IrvineLead Sponsor
545 Previous Clinical Trials
1,923,111 Total Patients Enrolled
Ariana Nelson, MDPrincipal InvestigatorAssociate Clinical Professor
1 Previous Clinical Trials
105 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger